Acute Severe Ulcerative Colitis - Clinical And Translational Studies
Funder
National Health and Medical Research Council
Funding Amount
$340,891.00
Summary
One in five patients with severe ulcerative colitis, a condition resulting in damage to the large bowel, may require surgery to remove the bowel. This project aims to find out how best to avoid surgery using a drug called infliximab which targets the immune system to reduce bowel damage. This study also aims to find changes in the immune system that cause ulcerative colitis and identify which patients are more likely to avoid surgery with infliximab thereby minimising side effects and costs.
Bioresponsive Porous Silicon For Site Specific Oral Delivery Of Antibodies For The Treatment Of Inflammatory Bowel Disease
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
This proposal aims to develop an oral antibody delivery system for treatment of inflammatory bowel disease (IBD) that affects 75000 Australians. The system will be based on porous silicon nanoparticles acting as a container to protect the antibodies, and bioresponsive coatings acting as gates to enable site specific protein delivery at the inflamed site of GI tract. The project not only holds promise for protein delivery for the treatment of IBD but other diseases like diabetes.
A Role For Double-stranded RNA-dependent Protein Kinase In Regulating Nod-like Receptor Signaling For Modulating Colitis And Colitis-associated Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$230,600.00
Summary
Inflammatory bowel disease (IBD) and Colorectal cancers (CRC) are commonly found in developed countries like Australia. In spite of improved treatment for IBD and CRC, it is still not known why many patients are still not responsive to these therapies. Therefore, this proposed project aims to use genetically modified mice and molecular biology techniques to understand the pathogenesis of these diseases and to find an alternative new treatment for these diseases.
Emu Oil And Protection From Experimentally-induced Ulcerative Colitis And Crohn's Disease
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
The inflammatory bowel diseases (IBD), encompassing ulcerative colitis and Crohn’s disease, are chronic intestinal inflammatory disorders of unknown cause. Current treatments for IBD are variably effective highlighting the need for improved therapeutic approaches. Emu Oil is reported to exert potent anti-inflammatory and antioxidant effects. Using well established experimental models, we seek to determine the potential efficacy and underlying mechanism of Emu Oil action in acute and chronic IBD.